Physiological Basis
Platelet-rich plasma (PRP) is produced by centrifuging autologous whole blood at high speed — typically 3,000 RPM or greater for 10 to 15 minutes — separating the platelet-rich plasma layer from the erythrocyte and leukocyte fractions. The resulting concentrate contains 3 to 5 times the baseline platelet concentration of whole blood. Upon injection into target tissue, platelets degranulate, releasing the contents of their alpha-granules: vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), and transforming growth factor beta-1 (TGF-β1). This growth factor milieu collectively drives the regenerative response within the corpus cavernosum.
At the cellular level, VEGF and PDGF stimulate vascular endothelial cell proliferation and migration, initiating angiogenesis and restoring microvasculature density within cavernosal tissue depleted by chronic arteriogenic disease. FGF and TGF-β1 support smooth muscle cell repair and extracellular matrix remodelling — directly relevant to the loss of corporal smooth muscle that characterises progressive organic ED. The activation of Schwann cells by growth factor signalling supports peripheral nerve repair in post-prostatectomy and post-surgical presentations, making PRP a component of several penile rehabilitation protocols.
Compared to second-generation PRF, PRP delivers its growth factor payload more rapidly upon injection — either spontaneously as platelets encounter tissue collagen, or via exogenous activation with thrombin or calcium chloride. This rapid-release kinetics profile differs from PRF's sustained fibrin-scaffold delivery, though both approaches share the same fundamental angiogenic and regenerative mechanism. The choice between them typically reflects physician training, institutional protocol, and the specific clinical objective.
The Treatment Protocol
A venous blood draw of 20 to 60 mL is collected into anticoagulant-containing tubes (sodium citrate or ACD-A). The sample undergoes high-speed centrifugation to separate cellular fractions and concentrate the platelet-rich plasma layer, which is aspirated under sterile conditions. EMLA topical anaesthetic cream is applied to the penile shaft 30 to 45 minutes prior to injection. Using a 27 to 30 gauge needle, intra-cavernosal injections are delivered bilaterally at multiple points along the penile shaft, with the physician distributing the PRP concentrate evenly through the erectile tissue. Gentle pressure is applied at each injection site following needle withdrawal.
The entire procedure, from blood draw through injection, is completed within 30 to 45 minutes. No sedation is required. Post-procedure instructions include light compression for 15 to 30 minutes, avoidance of vigorous physical activity and sexual activity for 24 to 48 hours, and avoidance of anti-inflammatory medications (NSAIDs, aspirin) for several days to avoid blunting the platelet-mediated inflammatory cascade that drives the regenerative response. A series of 1 to 3 treatments spaced 4 to 6 weeks apart is the typical clinical recommendation for cumulative benefit.
Who is a Candidate
PRP injection is indicated for men with mild-to-moderate organic erectile dysfunction with demonstrable vascular or tissue-level aetiology, including arteriogenic disease with partially preserved haemodynamic function. Post-radical prostatectomy patients undergoing penile rehabilitation — particularly those with nerve-sparing procedures — represent an important candidacy group, as the nerve-regenerative growth factor effects may augment the natural cavernosal nerve recovery process. Men with reduced penile sensitivity following surgical or radiation-based treatment of pelvic malignancy, and those seeking adjunctive augmentation of PDE5 inhibitor response, are also reasonable candidates. PRP is most frequently positioned as an adjunct within a multimodal protocol alongside Li-ESWT or shockwave therapy, rather than as monotherapy.
Contraindications include active platelet dysfunction, thrombocytopenia with platelet count below 100,000/μL, anticoagulation therapy with warfarin or novel oral anticoagulants (direct thrombin inhibitors, factor Xa inhibitors), haematological malignancy, and active penile infection or inflammation. Patients on chronic aspirin therapy may require a physician-directed hold period prior to treatment. Psychogenic ED without organic component is not an appropriate indication for intra-cavernosal growth factor therapy.
Expected Outcomes and Timeline
Published clinical data on PRP for erectile dysfunction demonstrates measurable improvement in IIEF (International Index of Erectile Function) domain scores in patients with mild-to-moderate organic ED. Effect sizes are moderate, and the evidence base — while growing — is heterogeneous in terms of PRP preparation protocols, platelet concentration targets, and injection techniques, making direct cross-study comparison challenging. Broadly, approximately 50 to 65% of appropriately selected patients report meaningful subjective improvement following a full treatment series. Response is not immediate; the angiogenic and tissue-remodelling processes unfold over 4 to 12 weeks following injection. Full assessment of treatment response should be deferred until 1 to 3 months post-final treatment.
PRP is most robustly supported as adjunctive therapy alongside PDE5 inhibitor optimisation and/or shockwave therapy, rather than as monotherapy for moderate-to-severe ED. In the post-prostatectomy rehabilitation context, PRP combined with daily tadalafil and vacuum erection device use is an established multimodal protocol at several high-volume sexual medicine centres. Maintenance re-treatment at 12-month intervals is common in patients who achieve a meaningful initial response.
Safety Profile and Risks
PRP's autologous derivation provides an excellent intrinsic safety profile. Immune-mediated reactions, infectious disease transmission, and hypersensitivity to the injectate are not applicable risks. The most frequently reported adverse effects are local and transient: minor bruising at the venepuncture site, mild injection-site discomfort, and transient swelling or firmness along the penile shaft resolving within 24 to 72 hours. Haematoma within the corpus cavernosum is uncommon with appropriate needle gauge selection and technique. Infection, while theoretically possible, is minimised by strict aseptic technique and is rarely reported in published case series.
Cost and Accessibility
PRP injection is generally priced per session, with series pricing offered for multi-treatment courses. Per-session cost is typically lower than PRF due to the simpler high-speed centrifugation processing, though variability exists based on geographic market and physician overhead. The primary cost driver is physician time and clinical overhead — consumable costs (centrifuge tubes, sterile drapes, needles, local anaesthetic) are modest. PRP injection for ED is a cash-pay procedure with no current insurance coverage for this indication.
Selecting a Qualified Provider
Physicians performing intra-cavernosal PRP injection should hold ABU board certification in urology and, ideally, active SMSNA membership reflecting ongoing engagement with sexual medicine evidence standards. Specific competency in intra-cavernosal injection technique is non-negotiable — inadvertent injection into incorrect anatomical planes, the urethra, or dorsal vascular structures carries potential for harm. Providers should be transparent about their specific PRP preparation protocol, including centrifugation speed, duration, and target platelet concentration. Clinics offering PRP within a comprehensive sexual medicine evaluation — including diagnostic workup to confirm organic aetiology before treatment — reflect the appropriate standard of care rather than offering injections without prior assessment.